Every material Form 8-K Skye Bioscience, Inc. has filed with the SEC since August 18, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Skye Bioscience's Chief Financial Officer John P. Sharp resigned effective September 8, 2026, and CEO Punit Dhillon was appointed principal financial and accounting officer. The company also gave notice to end its Master Services Agreement with Lohman & Associates on the same date, and Nasdaq confirmed the company regained compliance with the minimum bid price rule. The filing states Sharp's departure was not due to any disagreement with the auditors or the company on financial or operating matters.
Sharp resigned as CFO and principal financial and accounting officer effective September 8, 2026; the filing says there was no disagreement with auditors or the company on financial statements, internal controls, operations, policies or pra
Board appointed CEO Punit Dhillon as principal financial and accounting officer effective September 8, 2026; his employment terms are unchanged.
Company terminated the Master Services Agreement dated March 31, 2026 with Lohman & Associates, Inc., effective September 8, 2026.
Nasdaq letter received September 8, 2026 confirmed a closing bid price at or above $1.00 for 10 consecutive business days (August 24 through September 4, 2026), closing the matter.
On August 21, 2026, Skye Bioscience entered a Securities Purchase Agreement with an affiliate of Redmile Group under which the company can sell up to $22,000,000 of its common stock over three years, subject to conditions. The deal is tied to the proposed acquisition of Redx Pharma Limited and a related private placement, and the share sales would add to the number of shares outstanding.
Equity line of up to $22,000,000, reduced by any amount the funded PIPE exceeds $103,000,000; no shares are sold if the funded PIPE amount reaches $125,000,000 or more
Monthly sales capped at $2,000,000 of shares, priced at the lesser of the PIPE price and market price, with a floor 10% below the PIPE price
Warrant issued at closing to purchase shares equal to $5,000,000 divided by the PIPE price, exercisable from January 1, 2027 to January 1, 2030
Share issuances capped at 19.99% of outstanding common stock absent stockholder approval; company must file a resale registration statement within 10 business days of the closing date
Nasdaq notified Skye Bioscience on August 18, 2026 that its stockholders' equity of ($497,307), as reported in its June 30, 2026 quarterly report, falls short of the $2,500,000 minimum under Nasdaq Capital Market Listing Rule 5550(b)(1). The notice has no immediate effect on the listing, and the stock continues to trade as SKYE, but the company must submit a plan to regain compliance and says there is no assurance it will do so. The notice comes alongside a pending acquisition of Redx Pharma Limited, which adds uncertainty for shareholders.
Stockholders' equity was ($497,307) versus a $2,500,000 minimum under Nasdaq Listing Rule 5550(b)(1)
Stock continues to trade on the Nasdaq Capital Market under SKYE; the notice has no immediate effect on listing
Compliance plan due October 2, 2026; if accepted, Nasdaq can grant an extension to February 14, 2027
Company is evaluating alternatives and says there can be no assurance it will regain compliance; Redx transaction agreement is dated August 14, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Skye Bioscience, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →